Royalty Report: Drugs, Diagnostic, Genome – Collection: 260411

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Diagnostic
  • Genome
  • Antibody
  • Assay
  • Enzymes
  • cardiac
  • Delivery
  • Surgical
  • ribonucleic acid

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 260411

License Grant
Licensor grants a non-exclusive, worldwide license and sublicense, including the right to grant sublicenses through multiple tiers of sublicense, under the Patent Rights and Trade Secrets to make, have made, use, sell, have sold, offer for sale and import Licensee In Vitro Screening Reagents for use in the Field.
License Property
The patent is for Expression in Insect Cells of Genes with Overlapping Open Reading Frames, Methods and Compositions Therefor.

Licensee Product shall mean an adeno-associated virus with a SERCA2a transgene (AAV1/SERCA2a) enzyme replacement therapy, including, without limitation, Licensees proprietary MYDICAR product.

Field of Use
The purpose of this agreement is to develop a Licensee In Vitro Screening Reagent to be commercialized as part of an in vitro neutralizing antibody assay (NAb Assay) for use with Licensees Product.  

The Field shall mean the performance of Tests to determine the suitability of patients for treatment with Licensee Product.

IPSCIO Record ID: 203266

License Grant
Licensor grants, during the Term, an exclusive license, under the Technology to Licensee Products in the Field.
License Property
This technology includes, without limitation, MYDICAR® (AAV1/SERCA2a).

Mydicar is a genetically targeted enzyme replacement therapy being studied for use in patients with severe heart failure.  It is designed to increase the level of SERCA2a, a sarcoplasmic endoplasmic reticulum calcium (Ca2+) ATPase found in the membrane of the sarcoplasmic reticulum (SR). The SERCA2a gene is delivered to the heart via an adeno-associated viral vector.

Field of Use
The field is human therapeutics and prophylactics.

IPSCIO Record ID: 289169

License Grant
Licensor grants to the Swiss Licensee a worldwide, semi-exclusive license, without the right to sublicense, under the Licensor Licensed Patents to research, develop, make, have made, import, use, offer for sale and sell Licensor Licensed Products for use in the Field.

For Licensor Transplantation Field License, Licensor grants a worldwide, non-exclusive license, without the right to sublicense, under Licensor Licensed Patents to research, develop, make, have made, import, use, offer for sale and sell Licensor Licensed Products for use in the Transplantation Field.

For Licensor Future HGV Sequence Patent Rights, Licensor grants to a non-exclusive option to obtain one or more non-exclusive, worldwide licenses, or sublicenses, as the case may be, with a right to sublicense to Licensee Affiliates only, under the Licensor Future HGV Sequence Patent Rights, to make, have made, use, import, offer for sale and sell Licensor Licensed products.

License Property
Licensed Patents means the Licensor Licensed Patents and the Licensee Optioned Patents.

Products  means reagents, compositions or kits suitable for use in the Field or the Transplantation Field.

The patents include NANBV Diagnostics and Vaccines;  Heteroduplex Tracking Assay for Gene Typing; and, Polynucleotide Probes Useful for Screening for HCV.

Both Parties currently own or control certain patent rights relating to the hepatitis C virus (HCV).

Field of Use
The Licensees purpose is for use in assays for the detection of nucleic acid sequences for use in in vitro diagnostics, excluding use in Blood Screening, but without limiting the effect of the Blood Screening Agreement.

Field means the commercial use of human in vitro diagnostic products that detect nucleic acid sequences of HCV. Expressly excluded from the Field are products in Blood Screening; products specifically labeled or promoted for use in the Transplantation Field.

Transplantation Field means the commercial use of products that detect nucleic acid sequences for the screening of any biological materials intended for transfusion or transplantation, in each case from any donor, including autologous donors, other than the transfusion or transplantation of blood or its derivatives, components or replacements.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.